SHR-3032
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
October 15, 2024
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=6 | Completed | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Recruiting ➔ Completed | N=40 ➔ 6 | Trial completion date: Sep 2024 ➔ Apr 2024 | Trial primary completion date: Sep 2024 ➔ Mar 2024
Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Transplant Rejection • Transplantation
December 05, 2023
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Transplant Rejection • Transplantation
October 19, 2023
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
New P1 trial • Transplant Rejection • Transplantation
1 to 3
Of
3
Go to page
1